宾夕法尼亚州一家药店因在无管制设施中非法生产未经批准的重量损失药物而被罚款100万美元。 A Pennsylvania pharmacy was fined $1M for illegally making unapproved weight-loss drugs in unregulated facilities.

切斯特县药店Boothwyn药店因在未经批准、未经检查的设施中非法添加GLP-1重量损失药物,每天产生约1,000剂,因此被罚款100万美元,并被缓刑。 A Chester County pharmacy, Boothwyn Pharmacy, has been fined $1 million and placed on probation for illegally compounding GLP-1 weight-loss drugs in unapproved, uninspected facilities, producing about 1,000 doses daily. 在2024年11月至2025年3月期间的四次视察中,国家视察员不知道这些行动。 State inspectors were unaware of the operations during four visits between November 2024 and March 2025. 被承认违反州法律的药房必须在一年之内支付50万美元,并满足取消缓刑的严格要求,包括州检查和国家认证。 The pharmacy admitted violating state laws, must pay $500,000 within a year, and meet strict requirements—including state inspections and national accreditation—to lift probation. 该案突出表明,在对减重药品的需求不断上升的情况下,无管制地使问题复杂化,可能会带来风险。 The case underscores risks in unregulated compounding amid rising demand for weight-loss medications.